Featured Research

from universities, journals, and other organizations

Finding may pave way for new treatments for muscle wasting diseases

Date:
July 13, 2010
Source:
University of Aberdeen
Summary:
Scientists have discovered a mechanism that muscles use to regulate the nerves which control them. They believe their finding could yield new ideas for treating symptoms of motor neuron disease - a progressive and incurable neurodegenerative condition that leads to muscle weakness and wasting - and other neuromuscular conditions.

Scientists in Aberdeen have discovered a mechanism that muscles use to regulate the nerves which control them.

They believe their finding could yield new ideas for treating symptoms of motor neuron disease -- a progressive and incurable neurodegenerative condition that leads to muscle weakness and wasting -- and other neuromuscular conditions.

The University of Aberdeen researchers found that a protein produced by the muscle helps motor nerves -- nerves that tell our muscle to work -- produce a big enough stimulus to trigger muscle contraction.

Like a signal booster that improves TV pictures, the protein called TGFb2 amplifies the signal motor nerves use to activate muscle fibres.

This signalling process is crucial if our muscles are to respond properly -- especially during prolonged activity. This includes doing even relatively simple things like standing for long periods.

Dr Guy Bewick, Senior Lecturer at the University's Institute of Medical Sciences, said: "We knew this protein was in muscle cells near the motor nerve endings. It plays key roles elsewhere in the body, including the brain, controlling development or damage and infection responses, but we didn't understand what it did in normal, adult, healthy muscles.

"We have discovered that the protein boosts electrical signalling in our muscles, making the nerve-muscle communication secure and big enough to allow our muscles to contract. It also makes signalling more efficient, so nerves can produce the big signals for longer, during long-term activity.

"Our finding gives us a better understanding of how our nerve endings maintain the correct signalling strength as we grow, or take on new activities, like running or weight training.

"It could also point to new ways of treating symptoms of reduced nerve-muscle signalling, such as weakness and tiredness in early stages of motor neuron disease, when failing nerve endings might be boosted enough to work for longer."

The study -- published in Proceedings of the National Academy of Sciences -- was a collaboration involving the University of Aberdeen and the University of Otago, New Zealand.

It was launched after researchers in New Zealand discovered that if the protein was given to mice with early stages of motor neuron disease it improved muscle performance for several weeks, enabling them to run around for longer.

Motor neuron disease affects life expectancy and scientists were testing the theory that the protein's role in neuronal development might slow or prevent motor neuron death and prolong the life of these mice.

The mice did not live longer, but they did stay mobile for longer.

This latest study was designed to test how this occurred. The new findings suggest the protein restored lost signal strength to sick motor neurons, at least in the short term.

Dr Bewick added: "We hope that eventually this mechanism can be targeted with drugs to help people with neuromuscular diseases, where their nerve terminals don't work very well, to improve their quality of life.

"While uncovering this system is an extremely exciting first step, we also know that although harmless to mice, injections of pure TGFb2 can be highly toxic to humans.

"Now we know how TGFb2 works, however, we are looking for other ways to stimulate the same signalling system safely and in a controlled way.

"We are now looking for funding for this next step in its evaluation."


Story Source:

The above story is based on materials provided by University of Aberdeen. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sitt Wai Fong, Ian S. McLennan, Andrew Mcintyre, Jayne Reid, Kathleen I. J. Shennan, and Guy S. Bewick. TGF-β alters the characteristics of the neuromuscular junction by regulating presynaptic quantal size. Proceedings of the National Academy of Sciences, 2010; DOI: 10.1073/pnas.1001695107

Cite This Page:

University of Aberdeen. "Finding may pave way for new treatments for muscle wasting diseases." ScienceDaily. ScienceDaily, 13 July 2010. <www.sciencedaily.com/releases/2010/07/100713091437.htm>.
University of Aberdeen. (2010, July 13). Finding may pave way for new treatments for muscle wasting diseases. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100713091437.htm
University of Aberdeen. "Finding may pave way for new treatments for muscle wasting diseases." ScienceDaily. www.sciencedaily.com/releases/2010/07/100713091437.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins